Hims vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Willow beats Hims overall, scoring 8.2/10 vs 7.9/10. Hims is more affordable at $199/mo vs $299/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-appr. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side comparison of Hims and Willow covering pricing, scores, medication types, insurance, and more to help you decide.

Hims

#12 of 48

7.9/10

The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership — alongside their existing compounded semaglutide program. Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026) — significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28% — the highest 1-star rate in our table — clustered around subscription/billing complaints.

Visit Hims

Higher Rated

Willow

#8 of 48

8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	Hims	Willow
Our Score	7.9/10	8.2/10
Starting Price	$199/mo	$299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership — but should know going in that Hims' customer-experience signal is weaker than smaller competitors	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking	#12	#8

Pros & Cons Compared

Hims

Pros

+Publicly traded company (NYSE: HIMS) — SEC-filed financials, regulatory accountability that private competitors don't have.
+2026 Novo Nordisk partnership — FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
+$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
+Polished app and web experience — among the best user interfaces in men's telehealth.
+8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461) — significant real-world adoption.

Cons

−Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026) — significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
−28% of Trustpilot reviews are 1-star — the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
−Hims reviews span ALL their products (ED, hair loss, mental health, weight loss) — not just GLP-1. But the rating still applies because most users don't separate experiences by product.
−'Hims Oral Kit' is NOT a GLP-1 — it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
−Brand Wegovy at $599/mo is not competitive with LillyDirect/NovoCare cash prices or with Hers ($149/mo for the same product via the same Novo partnership).
−Generic high-volume support — large patient base means less personalized attention than smaller competitors.

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only — no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
−Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out Hims with a score of 8.2/10 vs 7.9/10. If budget is your priority, Hims starts at $199/mo compared to Willow's $299/mo. Hims offers both brand-name and compounded medications, giving you more flexibility. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership — but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hims nor Willow feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review